A phenomic and genomic approach to identifying pharmaceutical targets for the amelioration of hematopoietic deficit

采用表型组学和基因组学方法来确定改善造血缺陷的药物靶标

• 批准号: nhmrc : 305541
• 负责人: Prof Benjamin Kile
• 金额: $ 5.8万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phenomic-genomic-approach-hematopoietic-deficit/113938
• 关键词: phenomic; genomic; approach; identifying; pharmaceutical

Mice and humans are genetically and physiologically similar, and are afflicted by many of the same diseases. By introducing random DNA mutations into the germline, mice with diseaseassociated characteristics can be generated, allowing the subsequent identification of genes involved in particular human disease processes. This project will utilise cutting-edge genetic technologies to discover genes that regulate production of the body�s principal blood clotting agents: platelets. This is of particular clinical and commercial importance since a reduction in platelet numbers is the life-threatening result of congenital and autoimmune diseases, viral infections (e.g. HIV) and cancer chemotherapy.

老鼠和人类在遗传和生理上是相似的，并且受到许多相同疾病的折磨。通过将随机DNA突变引入种系，可以产生具有疾病相关特征的小鼠，从而允许随后鉴定参与特定人类疾病过程的基因。该项目将利用尖端的遗传技术来发现调节人体主要凝血因子血小板产生的基因。这具有特别的临床和商业重要性，因为血小板数量的减少是先天性和自身免疫性疾病、病毒感染（例如HIV）和癌症化疗的危及生命的结果。